Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicina (Kaunas)
Hauptverfasser: Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2019
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://ncbi.nlm.nih.gov/pubmed/31640191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge